The Dan Lewis Foundation Prize for Brain Regeneration Research Awarded to Dr. Roy Maimon
Dan Lewis Foundation | Summer 2023

As co-chairs of the Dan Lewis Foundation (DLF) for Brain Regeneration Research, we are pleased to announce University of California San Diego neuroscientist Dr. Roy Maimon as the first recipient of the DLF Prize. This accolade pays tribute to his groundbreaking work in advancing our understanding of the brain's regenerative capabilities. Dr. Maimon's research focuses on stimulating the brain to create new neurons, a crucial process in mitigating the detrimental effects of neurodegenerative diseases and injuries.


Over the past three years, Dr. Maimon has worked on this problem by testing a new concept for treating neurodegeneration: using cellular identity conversion to generate new neurons in the nervous system. Most recently, Dr. Maimon and colleagues have designed and executed experimental tests using antisense oligonucleotides (ASOs) to generate glia-to-neuron conversion in the adult rodent nervous system. These new neurons, created from radial gliallike cells and other GFAP-expressing cells, matured and functionally integrated into endogenous circuits over a two-month period, ultimately altering the behavior of the mice. This therapeutically viable approach opens up exciting prospects for producing new neurons to replace those lost due to neurodegenerative disease.


The DLF will follow future developments in this exciting and cutting-edge area with great attention. We hope that unlocking the ability to generate new functional neurons from existing brain cells will prove to be of real value to those with severe brain injuries. Dr. Maimon and his colleagues have produced intriguing results.


The DLF has closely tracked the impressive record of ASOs to successfully reduce the effects of neurodegenerative diseases in mammalian models as well as in humans. We believe that the work of Dr. Maimon and others doing similar research will also apply to brain regeneration in persons who have experienced ABI or TBI.


The DLF is excited by Dr. Maimon's research findings and will continue to follow his work in the field of brain regeneration. In Dr. Maimon's own words, "In upcoming years, I will seek a position as an academic investigator with the long-term goals of leading the field of in vivo glia-into-neurons cell identity conversion, being a part of finding cures for neurogenerative diseases, and successfully mentoring a new generation of young scientists who have a passion for understanding the brain.”


The Dan Lewis Foundation is committed to the support of excellent young scientists who are developing promising approaches to unlock the regenerative capacities of the brain. We proudly award Dr. Maimon the first DLF Prize for his groundbreaking work.


Maimon, Roy, Carlos Chillon-Marinas, Cedric E. Snethlage, Sarthak M. Singhal, Melissa McAlonis-Downes, Karen Ling, Frank Rigo, et al. 2021. "Therapeutically Viable Generation of Neurons with Antisense Oligonucleotide Suppression of PTB." Nature Neuroscience 24 (8): 1089–99.

By Dan Lewis Foundation | Spring 2024 11 Apr, 2024
Graham Dempsey, Ph.D., is a founder and Chief Scientific Officer (CSO) at Quiver Bioscience, a Cambridge, Massachusetts-based biotechnology company focused on the development of medicines for disorders of the nervous system. Dr. Dempsey and his team are working to develop treatments for some of the most challenging unsolved medical issues patients and their families face. Using advanced technologies in human stem cell biology, optogenetics, machine learning, and drug screening, progress is being made to develop medicines that will one-day treat conditions that have been largely untreatable. As the lead scientist for Quiver, formerly Q-State Biosciences, Dr. Dempsey enjoys working with world-class teams to invent, develop, and apply cutting-edge technologies to solve the most difficult challenges in biopharma for the betterment of patients. Dr. Dempsey’s inspiration to dedicate his professional life to science and medicine started at the early age of seven with the tragic loss of his father to an aggressive form of cancer, an experience that has deeply motivated him to this day. He completed his undergraduate studies at the University of Pennsylvania and his doctorate at Harvard University. As a graduate student in the biophysics program at Harvard Medical School, he co-developed ‘Stochastic Optical Reconstruction Microscopy’ or STORM , a light microscope with the ability to resolve nanometer (billionth of a meter, e.g. a hair is 100,000 nanometers thick) scale details of biological materials, an achievement that had been thought to be impossible for over a century. STORM has enabled what researchers call ‘super-resolution imaging’ for visualizing the intricate details of life’s most fundamental unit, the cell. Understanding the inner workings of a cell provides a path to a deeper understanding of the ways in which life is constructed and diseases can manifest. The technology was commercialized by Nikon Instruments for researchers worldwide. Dr. Dempsey left academic science to join Q-State Biosciences as the first hired employee with the goal of bringing advanced technologies developed at Harvard to the study of the brain. The brain, arguably the most complex structure in the known universe, works through electrical communication between brain cells or neurons. This communication is disrupted in all brain disorders but has been near impossible to study for the purposes of effectively developing medicines. Dr. Dempsey and his team over the course of ten years built a technology system that creates human brain models from patient stem cells (i.e. a ‘disease-in-a-dish’) and converts electrical activity of those brain cells into light signals that can be detected with ultra-sensitive microscopes. The resulting signals are analyzed using machine learning to find the patterns of how electrical activity is altered in disease, which can be used to find medicines that correct those changes. The team at Quiver is deploying this technology to take on previously untreatable brain conditions, including rare genetic diseases, such as certain seizure and neurodevelopmental disorders, to common conditions, such as chronic pain and Alzheimer’s disease. Dr. Dempsey’s passion outside of science starts with his family, his wife (and high school sweetheart) and three young daughters, be it traveling the globe to experience new cultures (or simply stare at the ocean), cooking elaborate meals on a Saturday evening, night-time reading of novels to his daughters, or attending live music around Boston. As a native of NJ, he celebrates his roots with visits to family near the Jersey Shore and, whenever possible, attendance at Springsteen concerts and Giants games. Dr. Dempsey is an avid student of history’s great entrepreneurs, spending the sparse remaining minutes of the day reading biographies and listening to podcasts, looking to extract every bit of learning towards taking on the challenges of building a great business while staying true to his family, his Quiver teammates, and his professional mission.
By Dan Lewis Foundation | Spring 2024 11 Apr, 2024
Sheryl Suzanne Nibbs, a legal secretary in a top law firm, started the process of becoming a paralegal as she approached her 40th birthday. She was fancy in her appearance, always making sure her hair, nails, and clothing were in order, a well-kept person, an avid traveler, and her mother’s best friend.
Share by: